Valneva SE (VLA):企業の財務・戦略的SWOT分析

◆英語タイトル:Valneva SE (VLA) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH456494FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:54
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥35,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥52,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Valneva SE (VLA) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Valneva SE (Valneva) is a biotechnology company that develops life-saving vaccines against infectious diseases and cancer. The company’s products include a vaccine indicated for the prevention of Japanese encephalitis and a vaccine indicated for the prevention of cholera and diarrhea. Its pipeline encompasses investigational candidates for the prevention of lyme, chikungunya, Zika virus, and infections caused by Clostridium difficile. The company works in partnership with various pharmaceutical and biopharmaceutical companies to develop its pipeline vaccine candidates and to distribute its products. The company sells its products in the Americas, Asia-Pacific, Europe, and the Middle East. It operates in Austria, Sweden, the UK, France, the US, and Canada. Valneva is headquartered in Saint-Herblain, France.

Valneva SE Key Recent Developments

Apr 07,2021: Valneva’s Covid-19 vaccine shows robust immune response in trial
Mar 24,2021: Valneva Publishes its FY 2020 Audited Consolidated Financial Statements
Mar 13,2021: Valneva Announces Supervisory Board Changes
Feb 25,2021: Valneva reports FY 2020 results and major corporate achievements
Jan 15,2021: Valneva announces amendment to Deerfield and OrbiMed debt facility terms

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Valneva SE – Key Facts
Valneva SE – Key Employees
Valneva SE – Key Employee Biographies
Valneva SE – Major Products and Services
Valneva SE – History
Valneva SE – Company Statement
Valneva SE – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Valneva SE – Business Description
Product Category: Dukoral
Overview
Performance
Key Stats
Product Category: Ixiaro/Jespect
Overview
Performance
Key Stats
Product Category: Lyme VLA15
Performance
Product Category: Other
Performance
Product Category: Third Party Products
Performance
Geographical Segment: Austria
Performance
Geographical Segment: Canada
Performance
Geographical Segment: Germany
Performance
Geographical Segment: Nordics
Performance
Geographical Segment: Other Europe
Performance
Geographical Segment: Rest of World
Performance
Geographical Segment: United Kingdom
Performance
Geographical Segment: United States
Performance
Valneva SE – Corporate Strategy
Valneva SE – SWOT Analysis
SWOT Analysis – Overview
Valneva SE – Strengths
Valneva SE – Weaknesses
Valneva SE – Opportunities
Valneva SE – Threats
Valneva SE – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Valneva SE, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Valneva SE, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Valneva SE, Recent Deals Summary
Section 5 – Company’s Recent Developments
Apr 07, 2021: Valneva’s Covid-19 vaccine shows robust immune response in trial
Mar 24, 2021: Valneva Publishes its FY 2020 Audited Consolidated Financial Statements
Mar 13, 2021: Valneva Announces Supervisory Board Changes
Feb 25, 2021: Valneva reports FY 2020 results and major corporate achievements
Jan 15, 2021: Valneva announces amendment to Deerfield and OrbiMed debt facility terms
Jan 11, 2021: Valneva strengthens management team; appoints Perry Celentano as interim COO and David Lawrence as acting CFO
Jan 07, 2021: Valneva reports FY 2020 cash of over €200 million
Nov 03, 2020: Valneva reports nine month results marked by further major corporate achievements
Sep 18, 2020: Valneva announces retirement of chief financial officer David Lawrence
Aug 06, 2020: Valneva announces appointment of Juan Carlos Jaramillo as Chief Medical Officer
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Valneva SE, Key Facts
Valneva SE, Key Employees
Valneva SE, Key Employee Biographies
Valneva SE, Major Products and Services
Valneva SE, History
Valneva SE, Subsidiaries
Valneva SE, Key Competitors
Valneva SE, Ratios based on current share price
Valneva SE, Annual Ratios
Valneva SE, Annual Ratios (Cont...1)
Valneva SE, Annual Ratios (Cont...2)
Valneva SE, Interim Ratios
Valneva SE, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Valneva SE, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Valneva SE, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Valneva SE (VLA):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Atrium Innovations Inc:企業の戦略的SWOT分析
    Atrium Innovations Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Pabst Brewing Company:企業の戦略・SWOT・財務分析
    Pabst Brewing Company - Strategy, SWOT and Corporate Finance Report Summary Pabst Brewing Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • DIC Corp (4631):企業の財務・戦略的SWOT分析
    DIC Corp (4631) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Mylan Laboratories Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Mylan Laboratories Ltd (Mylan), a subsidiary of Mylan NV is a pharmaceutical company that manufactures and supplies API products. The company offers HIV care products for the treatment of HIV/AIDS. It provides women’s care products for therapies such as hormone replacement therapy, infertili …
  • Caja Laboral Popular Coop. de Credito:企業の戦略・SWOT・財務情報
    Caja Laboral Popular Coop. de Credito - Strategy, SWOT and Corporate Finance Report Summary Caja Laboral Popular Coop. de Credito - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • NetScout Systems Inc (NTCT):企業の財務・戦略的SWOT分析
    NetScout Systems Inc (NTCT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Evotec AG (EVT):医療機器:M&Aディール及び事業提携情報
    Summary Evotec AG (Evotec) is a drug discovery alliance and development partnership company. It identifies and develops small molecule drugs across various therapeutic areas such as, cancer, neurological and nephrological conditions, cardiovascular, inflammation, pain, metabolic and respiratory dise …
  • Arris International Plc
    Arris International Plc - Strategy, SWOT and Corporate Finance Report Summary Arris International Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Fiesta Mart LLC:企業の戦略的SWOT分析
    Fiesta Mart LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Legg Mason, Inc.:戦略・SWOT・企業財務分析
    Legg Mason, Inc. - Strategy, SWOT and Corporate Finance Report Summary Legg Mason, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • General Dynamics Corp (GD):企業の財務・戦略的SWOT分析
    General Dynamics Corp (GD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Iridex Corp (IRIX):企業の財務・戦略的SWOT分析
    Summary Iridex Corp (Iridex) is a medical device company that manufactures and distributes laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology and otolaryngology market. The company offers products such as lasers, laser delivery devices, glaucoma device …
  • Luye Pharma Group Co Ltd (2186):製薬・医療:M&Aディール及び事業提携情報
    Summary Luye Pharma Group Co Ltd (Luye Pharma) is a pharmaceutical company that develops, produces and markets pharmaceutical products in the therapeutic areas of oncology, cardiovascular, metabolism and central nervous system. The company’s products include sodium aescinate for injection, xuezhikan …
  • Symrise AG (SY1):企業の財務・戦略的SWOT分析
    Symrise AG (SY1) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Suncor Energy Inc.:企業の戦略・SWOT・財務情報
    Suncor Energy Inc. - Strategy, SWOT and Corporate Finance Report Summary Suncor Energy Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Sanofi Genzyme:企業の戦略・SWOT・財務分析
    Sanofi Genzyme - Strategy, SWOT and Corporate Finance Report Summary Sanofi Genzyme - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • SoftBank Group Corp:企業の戦略・SWOT・財務分析
    SoftBank Group Corp - Strategy, SWOT and Corporate Finance Report Summary SoftBank Group Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • NicozDiamond Insurance Limited:企業の戦略・SWOT・財務分析
    NicozDiamond Insurance Limited - Strategy, SWOT and Corporate Finance Report Summary NicozDiamond Insurance Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Abercrombie & Fitch Co.:企業の戦略・SWOT・財務情報
    Abercrombie & Fitch Co. - Strategy, SWOT and Corporate Finance Report Summary Abercrombie & Fitch Co. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Arab National Bank:企業の戦略・SWOT・財務情報
    Arab National Bank - Strategy, SWOT and Corporate Finance Report Summary Arab National Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆